[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sally E. Wenzel MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100419597","phase-4-measuring-the-effect-of-dupilumab-treatment-on-mucociliary-clearance-mcc-in-subjects-with-moderate-to-severe-asthma-100419597",false,"NCT04743791","Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","A Randomized, Placebo-controlled, Parallel Group Study Designed to Assess the Change in Mucociliary Clearance After 12 Weeks of Treatment With Dupilumab in Patients With Moderate to Severe Asthma","Inclusion Criteria:\n\n* Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in one second (FEV1) \\\u003C90% predicted, on medium to high dose inhaled corticosteroids (ICS) with or without a second controller\n* Age \\> 18\n* Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)\n* Reversibility \\>\u002F= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening\n* FEV1\u002FForced Vital Capacity (FVC)\\\u003C75%\n* Blood Eosinophils (EOS) \\>300 cells per mm3\n* Exhaled Nitric Oxide (FeNO) \\>25 parts per billion (ppb)\n* Asthma Control Test (ACT) score \\\u003C20\n\nExclusion Criteria:\n\n* Pregnant, nursing, or unwilling to test for pregnancy\n* Current smoker or \\>10 pack year smoking history\n* Body Mass Index (BMI)\\>37\n* Respiratory infection in the last 30 days\n* Use of antibiotics or oral prednisone in the last 30 days\n* Current or previous use of dupilumab\n* Current or recent use of anti-IL-5 therapies\n* Any other criteria that place the subject at unnecessary risk\n* Diagnosis of other lung diseases including Chronic Obstructive Pulmonary Disease (COPD)\n* History of non-skin cell cancer in the last 5 years\n* Drug or alcohol addiction in the last 5 years\n* Any other uncontrolled disease","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.",[26],"Asthma","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-06","ACTUAL",{"date":33,"type":31},"2022-10-17",{"date":35,"type":20},"2028-06",{"name":37,"class":38},"Sally E. Wenzel MD","OTHER",""]